Merck KGaA (OTCMKTS:MKGAF) Sees Unusually-High Trading Volume - Should You Buy?

Key Points

• Unusual trading activity: Volume rose about 12% to 665 shares and the stock was up 3.1%, trading at $127.53 versus the prior close of $124.15.
• Financial snapshot: Market capitalization is about $16.55 billion with a P/E of 19.55, low leverage (debt-to-equity 0.27) but modest liquidity (quick ratio 0.84, current ratio 1.31).
• Technical and corporate context: The share price sits below both the 50-day ($144.23) and 200-day ($139.64) moving averages; Merck KGaA is a long-established, family-controlled German chemical and pharmaceutical group operating globally.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report) saw an uptick in trading volume on Thursday . 665 shares traded hands during mid-day trading, an increase of 12% from the previous session's volume of 593 shares.The stock last traded at $127.53 and had previously closed at $124.15.

Merck KGaA Stock Up 3.1%

The company has a market capitalization of $16.55 billion, a PE ratio of 19.55 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The company's 50-day moving average is $144.23 and its 200 day moving average is $139.64.

About Merck KGaA

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.